← All stories
Markets
MGC Pharmaceuticals back in the frame today — where does clinical cannabis go next?
Highlights MGC Pharmaceuticals remained a reference point for main-market cannabis exposure Clinical evidence has become the sector's primary valuation driver Development-stage biotech risks apply squarely to cannabinoid medicine MGC Pharma…
Covered by 1 outlet
All coverage · 1 article